Efficacy of intrathecal methotrexate in children with high-risk medulloblastoma over three years: a retrospective study from a single center
ConclusionsOur findings support the addition of intrathecal MTX during chemotherapy as the optimal management for children with group 3 and SHH high-risk MB. However, it is not recommended for group 4 MB patients, especially in resource-limited regions.Trial registration number: Retrospective registered No.(2020 − 117).
Source: Journal of Neuro-Oncology - Category: Cancer & Oncology Source Type: research
More News: Brain | Cancer & Oncology | Chemotherapy | Children | Cytology | Medulloblastoma | Methotrexate | Neurology | Study